INTRODUCTION
• Cushing's disease (CD) is a severe disease, associated with an increased rate of comorbidities and mortality. 1 • Remission rate after surgery of pituitary tumor is around 78%. Relapse occurs in 13% of patients within 10 years after surgery. 1 • According to guidelines, patients who undergo noncurative surgery, or for whom surgery is not possible, require additional treatment, including medical therapies. 2 • Metyrapone, inhibits 11β-hydroxylase enzyme, blocking the final step of cortisol synthesis in adrenal cortex ( Figure 1) . Daily dosage ranges from 250 to 6000 mg. 
PATIENTS AND METHODS
• PROMPT is an international European Phase III/IV study that commenced in 2015 (ClinicalTrial.gov registry: NCT02297945).
• PROMPT is the first prospective study to document the safety and efficacy of metyrapone using modern assay techniques, in endogenous Cushing's syndrome over 36 weeks.
• In Belgium, four patients with CD (three women and one man) were treated with metyrapone for the duration of the 9-month PROMPT study.
• One patient had received prior medical treatment with ketoconazole and cabergoline and three patients had received prior pituitary surgery.
• Metyrapone was individually titrated during the first 3 months of PROMPT based on urinary free cortisol (UFC) and/or serum cortisol performed at each visit ( Figure 2 ).
• UFC measurements during the study was performed centrally by liquid chromatography tandem-mass spectrometry (LC-MS/MS) method.
• An extension period of 6 months was proposed for patients whose mean UFC normalized or did not exceed twice the upper limit of normal (ULN = 165 nmol/24h) ( Figure 2 ).
• All four patients benefited after study end from further therapy with metyrapone through a medical need program. Three patients were treated for an additional 15 months (total 24 months) and one patient for an additional 12 months (total 21 months). -Baseline mean UFC of the fourth patient decreased by more than 50% after 9 months of therapy to 235 nmol/24h.
• Control of UFC levels was maintained during the study with a metyrapone dosage of between 500 mg and 5750 mg, divided into 3-4 intakes per day ( Table 1 ).
• Adrenocorticotropic hormone (ACTH) remained unchanged after the first 3 months of therapy, except for one patient who needed 5750 mg/day of metyrapone (3.2-fold increase in ACTH, Table 1 ). The baseline mean UFC was also the highest in this patient.
• Three patients maintained control of UFC levels after 24 months of treatment (as at December 2017).
• Despite maintaining disease control with metyrapone, the fourth patient (Patient #2) decided after 21 months of treatment to undergo bilateral adrenalectomy. 
SAFETY AND TOLERABILITY
• Four patients had fatty deposits before treatment, which resolved in three of the patients; two patients developed bruising, which resolved in both patients.
• Patients experienced transient mild to moderate AEs during the 9 months of the PROMPT study: nausea (n=1), fatigue (n=2), tiredness (n=2), dizziness (n=1), migraine (n=1), loss of appetite (n=1) and arthralgia (n=1) ( Table 2 ).
• Safety and tolerability were acceptable during the extension period after the 9-month study. Only one woman (Patient #3) developed hirsutism after one year of treatment, treated with cyproterone acetate. No acne was observed. 
CONCLUSION
• Metyrapone showed good efficacy with control of cortisol based on mean UFC.
• Metapyrone has an acceptable safety and tolerability profile in the long-term management (up to 24 months) of four patients with CD.
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